## **CLAIMS**

## 1. An 8-oxoadenine compound shown by the formula (1):

$$R^{1}$$
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{3}$ 
 $X^{3}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{4}$ 
 $X^{5}$ 
 $X^{6}$ 
 $X^{6}$ 
 $X^{6}$ 
 $X^{6}$ 
 $X^{6}$ 
 $X^{7}$ 
 $X^{7$ 

5

wherein ring A represents a 6-10 membered aromatic carbocyclic ring or a 5-10 membered heteroaromatic ring;

R represents a halogen atom, an alkyl group, a hydroxyalkyl group, a haloalkyl group, an alkoxy group, a hydroxyalkoxy group, a haloalkoxy group, amino group, an alkylamino group, a dialkylamino group, or a cyclic amino group;

n represents an integer of 0-2, and when n is 2, the Rs may be the same or different:

Z1 represents a substituted or unsubstituted alkylene group or a substituted or unsubstituted cycloalkylene group;

X<sup>2</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>5</sup>, CO, CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>, NR<sup>5</sup>CONR<sup>6</sup> or NR<sup>5</sup>CSNR<sup>6</sup> (in which R<sup>5</sup> and R<sup>6</sup> are each independently hydrogen atom, a substituted or unsubstituted alkyl group, and a substituted or unsubstituted cycloalkyl group);

Y1, Y2 and Y3 represent each independently a single bond or an alkylene group;

X1 represents oxygen atom, sulfur atom, SO2, NR4 (wherein R4 is hydrogen atom or an alkyl group) or a single bond;

R<sup>2</sup> represents hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group or a substituted or unsubstituted cycloalkyl group; and

R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group, a haloalkyl group, a haloalkoxy group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl

15

10

20

25

group or a substituted or unsubstituted cycloalkyl group, or its pharmaceutically acceptable salt.

5

10

15

20

25

30

35

The 8-oxoadenine compound according to claim 1, wherein ring A 2. represents a 6-10 membered aromatic carbocyclic ring, or a 5-10 membered heteroaromatic ring containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms; R represents a halogen atom, an alkyl group of 1-6 carbons, a hydroxyalkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a hydroxyalkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, amino group, an alkylamino group of 1-6 carbons, a dialkylamino group in which each alkyl moiety has 1-6 carbons, and a cyclic amino group; n is an integer of 0-2, and when n is 2, Rs may be the same or different; Z<sup>1</sup> represents an alkylene group of 1-6 carbons or a cycloalkylene group of 3-8 carbons, which is optionally substituted by hydroxy group; X<sup>2</sup> represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR<sup>5</sup>, CO, CONR<sup>5</sup>, NR<sup>5</sup>CO, SO<sub>2</sub>NR<sup>5</sup>, NR<sup>5</sup>SO<sub>2</sub>, NR<sup>5</sup>CONR<sup>6</sup> or NR<sup>5</sup>CSNR<sup>6</sup> (in which R<sup>5</sup> and R<sup>6</sup> are independently hydrogen atom, a substituted or unsubstituted alkyl group of 1-6 carbons, and a substituted or unsubstituted cycloalkyl group of 3-8 carbons, wherein the substituents of the alkyl group or cycloalkyl group are selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, carboxy group, an alkoxycarbonyl group of 2-5 carbons, carbamoyl group, amino group, an alkylamino group of 1-6 carbons, an dialkylamino group in which each alkyl moiety has 1-6 carbons, a cyclic amino group, carboxy group and tetrazolyl group which may be substituted by an alkyl group of 1-6 carbons.);

Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> represent each independently a single bond or an alkylene group of 1-6 carbons;

X¹ represents oxygen atom, sulfur atom, SO<sub>2</sub>, NR⁴ (wherein R⁴ represents hydrogen atom or an alkyl group) or a single bond;

R<sup>2</sup> represents a substituted or unsubstituted alkyl group of 1-6 carbons, a substituted or unsubstituted alkenyl group of 2-6 carbons, a substituted or unsubstituted alkynyl group of 2-6 carbons or a substituted or unsubstituted cycloalkyl group of 3-8 carbons (wherein the substituent in the alkyl group, alkenyl group and alkynyl group is selected from a halogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an acyloxy group of

2-10 carbons, amino group, an alkylamino group of 1-6 carbons, a dialklylamino group in which the each alkyl moiety has 1-6 carbons, and a cyclic amino group); and

R¹ represents hydrogen atom, hydroxy group, an alkoxy group of 1-6 carbons, an alkoxycarbonyl group of 2-5 carbons, a haloalkyl group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, a substituted or unsubstituted aryl group of 6-10 carbons, a substituted or unsubstituted 5-10 membered heteroaryl group containing 1-4 hetero atoms selected from 0-4 nitrogen atoms, 0-2 oxygen atoms and 0-2 sulfur atoms, or a substituted or unsubstituted cycloalkyl group of 3-8 carbons;

and the said substituent in the aryl group, the heteroaryl group and the cycloalkyl group is selected from a halogen atom, hydroxy group, an alkyl group of 1-6 carbons, a haloalkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, a haloalkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons, amino group, an alkylamino group of 1-6 carbons and a dialkylamino group (wherein the each alkyl group has 1-6 carbons), and the said cyclic amino group represents a 4-7 membered saturated cyclic amino group containing 1-2 hetero atoms selected from 1-2 nitrogen atoms, 0-1 oxygen atom and 0-1 sulfur atom, which may be substituted with a halogen atom, hydroxy group, oxo group, an alkyl group of 1-6 carbons, an alkoxy group of 1-6 carbons, an alkylcarbonyl group of 2-5 carbons or an alkoxycarbonyl group of 2-5 carbons, in the formula (1) of

or its pharmaceutically acceptable salt.

the calim 1,

5

10

15

20

25

30

35

- 3. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 1 or 2, wherein X<sup>2</sup> in the formula (1) of the calim 1 is oxygen atom, sulfur atom, NR<sup>5</sup>, SO<sub>2</sub>, NR<sup>5</sup>SO<sub>2</sub> or NR<sup>5</sup>CONR<sup>6</sup>.
  - 4. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1-3, wherein  $Y^3$  in the formula (1) of the calim 1 is a single bond, methylene or ethylene.
  - 5. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1 to 4, wherein  $Z^1$  in the formula (1) of the calim 1 is a straight chained alkyelne group of 1-6 carbons which may be substituted with hydroxy group.
  - 6. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1-5, wherein  $X^1$  in the formula (1) of the

calim 1 is oxygen atom or sulfur atom.

- 7. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1-6, wherein  $Y^1$  in the formula (1) of the calim 1 is a single bond or an alkylene group of 1-6 carbons.
- 8. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1-7, wherein R<sup>1</sup> in the formula (1) of the calim 1 is hydrogen atom, an alkoxycarbonyl group, hydroxy group, or an alkoxy group.
- 9. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to any of claims 1-8, wherein a group shown by the formula (2) in the formula (1) of the calim 1:

$$(R)_n$$
 COOR<sup>2</sup> (2)

5

10

15

20

25

(wherein ring A, R, n,  $Y^3$  and  $R^2$  have the same meaning as in the formula (1))

is a group shown by the formula (3) or the formula (4):

$$R^3$$
 $COOR^2$ 
 $R^3$ 
 $COOR^2$ 
 $R^3$ 
 $R^3$ 

(wherein R, n and R<sup>2</sup> have the same meaning as in the formula (1), and R<sup>3</sup> is hydrogen atom or an alkyl group).

- 10. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9, wherein R<sup>2</sup> is methyl group or an alkyl group of 2-6 carbons substituted by a dialkylamino group or a cyclic amino group.
- 11. The 8-oxoadenine compound or its pharmaceutically acceptable salt according to claim 9 or 10, wherein R<sup>3</sup> is hydrogen atom.
- 12. A pharmaceutical composition comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 as an active ingredient.
- 13. An immuno-modulator comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 as an

active ingredient.

5

10

15

20

25

30

- 14. A therapeutic or prophylactic agent for viral diseases, cancers or allergic diseases comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 as an active ingredient.
- 15. A medicament for topical administration comprising the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 as an active ingredient.
- 16. A use of the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 as a medicament.
- 17. A use of the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 for manufacturing an immuno-modulator.
- 18. A use of the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11 for manufacturing a therapeutic or prophylactic agent for viral diseases, cancers and allergic diseases.
- 19. A method for modulating immune response which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11.
- 20. A method for treating or preventing viral diseases, cancers and allergic diseases which comprises administering to a patient, an effective amount of the 8-oxoadenine compound or its pharmaceutically acceptable salt as claimed in any of claims 1-11.
- 21. A process for preparing the 8-oxoadenine compound as claimed in any of claims 1-11 which comprises brominating a compound shown by the formula (10):

$$R^{1}$$
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{3$ 

wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same

defined in the claim 1,

reacting the resultant with a metal alkoxide and then hydrolyzing, or hydrolyzing the resultant.

22. A compound shown by the formula (10):

$$R^{1}$$
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{3$ 

wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1.

23. A process for preparing the 8-oxoadenine compound as described in any of claim 1-11 which comprises deprotecting a compound shown by the formula (11):

$$R^{1}$$
 $X^{1}$ 
 $X^{1$ 

wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same defined in the claim 1.

24. A compound shown by the formula (11):

$$R^{1}$$
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{1}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{3$ 

wherein ring A, n, R, R<sup>1</sup>, R<sup>2</sup>, X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Z<sup>1</sup> are the same

5

10

15

defined in the claim 1.

25. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of the following compounds:

2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(3-methoxycarbonylmethylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylmethylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylmethylphenoxy)ethyl]adenine,

2-Butoxy-8-oxo-9-{2-[4-(2-methoxycarbonylethyl)phenoxy]ethyl}adenine,

2-Butoxy-8-oxo-9-[4-(3-

methoxycarbonylbenzenesulfonamide)butylladenine,

2-Butoxy-8-oxo-9-[4-(3-

methoxycarbonylmethylbenzenesulfonamide)butyl]adenine,

15 2-Butoxy-8-oxo-9-[4-(3-

5

10

methoxycarbonylphenylaminocarbonylamino)butyl|adenine,

2-Butoxy-8-oxo-9-[4-(3-

methoxycarbonylmethylphenylaminocarbonylamino)butyl|adenine,

Methyl [3-({[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

20 yl)ethyl]amino}methyl)phenyl]acetate,

[3-({[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)ethyl|amino}methyl)phenyl|acetic acid,

Methyl 3-({[3-(6-mino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino}methyl)benzoate,

25 3-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino}methyl)benzoic acid,

Methyl 4-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)propyl]amino}methyl)benzoate,

4-({[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

30 yl)propyllamino}methyl)benzoic acid,

Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-9H-purin-9-yl)propyl](2-morpholin-

4-ylethyl)amino|methyl)phenyl)acetate,

Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)butyl|amino|methyl|phenyl|acetate,

35 Ethyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-

yl)ethoxy|benzoate,

```
3-(Dimethylamino)propyl 2-[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-
          purin-9-yl)ethoxylbenzoate,
          Methyl 3-[4-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
         yl)butyl|amino|sulfonyl|phenyl|propanoate,
          3-[4-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
 5
         yl)butyl|amino}sulfonyl)phenyl|propanoic acid,
         Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
          pyrrolidin-1-ylethyl)amino|sulfonyl)phenyl)acetate,
          (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
          pyrrolidin-1-ylethyl)amino|sulfonyl}phenyl)acetic acid,
10
         Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
          methoxyethyl)amino|sulfonyl}phenyl)acetate,
          (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
          methoxyethyl)amino|sulfonyl}phenyl)acetic acid,
         Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
15
         yl)butyl](methyl)amino|sulfonyl}phenyl)acetate,
          (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
         yl)butyl|(methyl)amino|sulfonyl}phenyl)acetic acid,
          Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl})butyl][3-
          (dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)phenyl]acetate,
20
          [3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-
          (dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)phenyl]acetic acid,
          Methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
         yl)propyl]amino}sulfonyl)phenyl]acetate,
         Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
25
          hydroxy-2-methylpropyl)amino|sulfonyl)phenyl)acetate,
          (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
          hydroxy-2-methylpropyl)amino|sulfonyl}phenyl)acetic acid,
          Methyl [3-({[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
          yl)ethyl]amino}sulfonyl)phenyl]acetate,
30
          Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
          yl)butyl][(2R)-2,3-dihydroxypropyl]amino}sulfonyl)phenyl]acetate,
          [3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][(2R)-2,3-
          dihydroxypropyl]amino}sulfonyl)phenyl]acetic acid,
          Methyl 3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl][3-
35
```

(dimethylamino)-2,2-dimethylpropyl]amino}sulfonyl)benzoate,

3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl|amino}sulfonyl)benzoic acid, Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](3morpholin-4-ylpropyl)amino|methyl}phenyl)acetate, (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](3-5 morpholin-4-ylpropyl)amino|methyl}phenyl)acetic acid, Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyllamino\methyl)phenyl\acetate, [3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(dimethylamino)-2,2-dimethylpropyl]amino}methyl)phenyl]acetic acid, 10 Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(2-oxopyrrolidin-1-yl)propyl|amino}methyl)phenyl]acetate, [3-({[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][3-(2oxopyrrolidin-1-yl)propyl|amino}methyl)phenyl|acetic acid, Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-15 morpholin-4-ylethyl)amino|methyl}phenyl)acetate, (3-{[[4-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2morpholin-4-ylethyl)amino|methyl}phenyl)acetic acid, Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-20 yl)propyl](3-morpholin-4-ylpropyl)amino|methyl}phenyl)acetate, Methyl [3-({[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)butyl][2-(1H-tetrazol-5-yl)ethyl|amino|methyl)phenyl|acetate, Methyl (3-{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9yl)ethyl]thio}phenyl)acetate, (3-{[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-25 yl)ethyl]thio}phenyl)acetic acid, Methyl (3-{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9yl)ethyl|amino|phenyl|acetate, Methyl (3-{[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9yl)propyl]amino}phenyl)acetate, 30 (3-{[3-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9yl)propyl]amino}phenyl)acetic acid, Methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9yl)propyllamino\methyl)phenyllacetate, ([3-({[3-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-35

yl)propyl]amino}methyl)phenyl]acetic acid,

Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](2-

```
methoxyethyl)amino|methyl}phenyl)acetate,
         (3-{[[2-(6-Amino-2-butoxy-8-methoxy-9H-purin-9-yl)ethyl](2-
         methoxyethyl)amino|methyl}phenyl)acetic acid,
         Methyl (3-{[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
5
         yl)ethyl|sulfonyl}phenyl)acetate,
         Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
         yl)ethyl](methyl)amino|methyl}phenyl)acetate,
         (3-{[[2-(6-Amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-
         yl)ethyl](methyl)amino|methyl}phenyl)acetic acid,
10
         Methyl 4-[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)-2-
         hydroxypropoxy|benzoate,
         Methyl (3-{[[2-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)ethyl](2-
         hydroxyethyl)amino|methyl}phenyl)acetate,
         Methyl (3-{[[4-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl]butyl](2-
15
         hydroxyethyl)amino|methyl}phenyl)acetate,
         2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylphenoxy)ethyl]adenine,
         2-Butoxy-8-oxo-9-[2-(3-hydroxycarbonylmethylphenoxy)ethyl]adenine,
         2-Butoxy-8-oxo-9-[2-(2-methoxycarbonylphenoxy)ethyl]adenine,
         2-Butoxy-8-oxo-9-[2-(2-hydroxycarbonylmethylphenoxy)ethyl]adenine,
20
         2-Butoxy-8-oxo-9-[2-(4-hydroxycarbonylphenoxy)ethyl]adenine,
         2-Butoxy-8-oxo-9-[2-(4-methoxycarbonylmethylphenoxy)ethyl]adenine,
         2-Butoxy-8-oxo-9-{2-[4-(2-hydroxycarbonyolethyl)phenoxy]ethyl}adenine,
         2-Butoxy-8-oxo-9-[4-(3-hydroxycarbonylbenzenesulfonamide)butyl]adenine,
         2-Butoxy-8-oxo-9-[4-(3-
25
         hydroxycarbonylmethylbenzenesulfonamide)butyl|adenine,
         2-Butoxy-8-oxo-9-[4-(3-
         hydroxycarbonylphenylaminocarbonylamino)butylladenine and
         2-Butoxy-8-oxo-9-[4-(3-
         hydroxycarbonylmethylphenylaminocarbonylamino)butyl]adenine.
30
```